An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key i...

Descripción completa

Detalles Bibliográficos
Autores principales: Charlton, Michael R., Alam, Altaf, Shukla, Akash, Dashtseren, Bekhbold, Lesmana, Cosmas Rinaldi Adithya, Duger, Davadoorj, Payawal, Diana Alcantara, Duy Cuong, Do, Jargalsaikhan, Ganbolor, Cua, Ian Homer Yee, Sollano, Jose Decena, Singh, Karam Romeo, Madan, Kaushal, Win, Khin Maung, Kyi, Khin Pyone, Tun, Kyaw Soe, Salih, Mohd., Rastogi, Mukul, Saraf, Neeraj, Thuy, Pham Thi Thu, Hien, Pham Tran Dieu, Gani, Rino Alvani, Mohamed, Rosmawati, Tanwandee, Tawesak, Piratvisuth, Teerha, Sukeepaisarnjaroen, Wattana, Naing, Win, Hashmi, Zahid Yasin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452871/
https://www.ncbi.nlm.nih.gov/pubmed/32666200
http://dx.doi.org/10.1007/s00535-020-01698-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452871/
https://www.ncbi.nlm.nih.gov/pubmed/32666200
http://dx.doi.org/10.1007/s00535-020-01698-4

Ejemplares similares